LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases... Show more
A.I.dvisor indicates that over the last year, LBRX has been loosely correlated with IMNM. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LBRX jumps, then IMNM could also see price increases.
| Ticker / NAME | Correlation To LBRX | 1D Price Change % | ||
|---|---|---|---|---|
| LBRX | 100% | +0.14% | ||
| IMNM - LBRX | 37% Loosely correlated | -5.34% | ||
| KYTX - LBRX | 36% Loosely correlated | -5.03% | ||
| TSHA - LBRX | 36% Loosely correlated | -2.95% | ||
| LXEO - LBRX | 35% Loosely correlated | -4.35% | ||
| MGTX - LBRX | 35% Loosely correlated | -6.17% | ||
More | ||||
Industry Biotechnology
The RSI Indicator for LBRX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 1 similar instances when the indicator left oversold territory. In 1 of the 1 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 10 of 10 cases where LBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for LBRX just turned positive on October 15, 2026. Looking at past instances where LBRX's MACD turned positive, the stock continued to rise in 12 of 12 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where LBRX advanced for three days, in 47 of 52 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
LBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
LBRX moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for LBRX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.678) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.